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Simple Summary: Patients may develop white or red patches of the lining of the mouth with an
increased risk of developing oral cancer. Treatment with Vitamin A derivatives (retinoids) results in
some improvement in these lesions, but this is not maintained, and there are side effects. We know
that the cells of the mouth lose cellular receptors for retinoids as these lesions develop, initially by
a reversible alteration to the DNA (DNA methylation). Drugs, such as 5-AZA-CdR, which reduce
DNA methylation, may restore sensitivity to the effects of retinoids. Treatment of a panel of cells
from mouth precancer white patches with retinoids, 5-AZA-CdR and a combination results in varied
responses: some cells re-sensitise to retinoids, whereas in others, the main effects on cell division
rate and cell lifespan seem related to the effects of 5-AZA-CdR alone. These findings help us to
understand the varied responses to retinoids in the clinical setting.
Abstract: Loss of RARβ2 expression by promoter methylation is an early event in oral carcinogenesis.
Understanding the mechanisms and consequences of RARβ loss may aid in understanding the
disappointing results of retinoid chemoprevention trials. This study aimed to describe the effects of
all-trans retinoic acid (ATRA) and the de-methylating agent 5-Aza-2′ deoxycytidine (5-AZA-CdR) on
a panel of immortal potentially malignant oral lesion (PMOL) cell cultures. RARβ expression was
assessed in PMOL tissues by immunohistochemistry. Cells were treated with ATRA ± 5-AZA-CdR,
and the effects on the cell cycle and senescence were assessed. In PMOL tissues, RARβ expression
was variable, but lower in biopsies which gave rise to immortal cell cultures. Treatment of iPMOL
cells with ATRA resulted in little change in RARβ expression, but the addition of 5-AZA-CdR resulted
in significant increases. The effects on the cell cycle and senescence were variable and may be related
to 5-AZA-CdR, as this has wider effects on the cell cycle. Overall, the response of iPMOL cells
to ATRA and 5-AZA-CdR treatment was variable and is dependent on several factors, including
RARβ-promoter methylation. These findings may help to explain the lack of consistent effect of
retinoids in PMOLs seen in chemoprevention trials.
Keywords: RARβ; oral cancer; oral potentially malignant lesions; PMOL; retinoids; chemoprevention
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1. Introduction
Potentially malignant oral lesions (PMOLs) present variably in the mouth, including
white or red lesions (leukoplakia and erythroplakia). The risk of the development of
oral squamous cell carcinoma (OSCC) in such lesions has been related to several factors,
including patient age, the size, clinical appearance and site of the lesion, and degree
of epithelial dysplasia [1,2]. There is, however, a lack of validated biomarkers for the
prediction of malignant transformation [3]. Given the well-established concept of field
cancerisation of the oral mucosa, it has been demonstrated that the underlying molecular
lesion within the oral mucosa may be significantly more extensive than either the clinical
or histological abnormality [4]. The extent of this genetic abnormality means that it may
not be possible, or even desirable, to eradicate this by surgical means, even if the clinically
evident lesion can be removed. Thus, there has been much interest in (chemo)prevention
of progression to OSCC over many years.
Much of the interest in chemopreventative agents has focussed on Vitamin A and
related compounds, often referred to collectively as retinoids. Initial studies used topical
Vitamin A, but subsequent clinical investigations used a number of naturally occurring or
synthetic analogues, including 13-cis-retinoic acid [5–7]. Several moderately sized clinical
trials have been completed using these agents. Whilst initially promising, with reductions
in the size of clinical lesions, the overall long-term outcomes in terms of cancer prevention
were variable [6,8–10]. Additionally, some authors reported significant side effects and
relapse of lesions after cessation of treatment [11]. In summarising this literature, the
Cochrane review of interventions in oral leukoplakia concluded that there is currently
insufficient high-quality evidence for any intervention which will reduce the malignant
transformation rate in OPMLs [12]. This has resulted in less interest in the literature on the
effects of retinoids and other vitamin A analogues for OSCC prevention in recent years.
The effects of retinoids on oral mucosa are complex. In general, treatment of oral
epithelial cells with retinoids results in inhibition of cell proliferation and terminal differen-
tiation [13]. The expression of certain retinoic acid receptors in normal oral keratinocytes
depends on retinoid treatment. In some mortal cell cultures derived from PMOLs, constitu-
tive expression of the retinoid receptor Retinoic Acid Receptor Beta (NR1B2, HGNC: 9865,
hereafter referred to as RARβ) has been described [14]. However, in the progression of
PMOLs to OSCC, loss of certain retinoid receptors has been described in both cell/tissue
types, most notably the RARβ isoform RARβ2 [14,15]. There are four isoforms of RARβ
which have been generated by alternative splicing (www.uniprot.org/uniprot/P1082, ac-
cessed on 5 August 2021). Loss of RARβ2 has been associated with a number of other
well-established alterations in oral epithelial cells on progression to OSCC via PMOLs,
namely, loss of p16INK4a expression, p53 mutations and activation of telomerase [16]. This
combination of alterations has been associated with the bypass of replicative senescence,
allowing cells to become immortal. The basis of loss of RARβ2 expression, which may
occur at the PMOL stage, is hypermethylation of the RARβ2 promoter [17]. The role of
other associated molecules which are important in the modulation of retinoid receptor
signalling, such as the cellular retinoid-binding proteins (cRPBs) [18], in this context is
not known.
Various approaches have been reported to address these issues associated with retinoid
therapy of PMOLs, including the use of newer synthetic retinoid analogues (for exam-
ple, fenretinide: [9] and studies focussed on the identification of biomarkers, which may
predict retinoid sensitivity [9,19–22]. A further possible approach has been used in other
cancers: the addition of de-methylating agents to retinoids treatment. These agents, in-
cluding 5-aza-2′-deoxycytidine (5-AZA-CdR), have been used clinically in the treatment
of myelodysplastic syndromes and AML, where retinoid therapy is also employed. The
effects of such combinations have been reported in vitro and in vivo clinical studies, with
promising effects [23,24]. The approach has also been assessed in solid tumours, such as
breast carcinoma and neuroblastoma [25,26]. Proof of principle has already been estab-
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lished in PMOL and OSCC cells [16,17], but an in-depth assessment of the functional effects
in PMOLs has not been reported.
This raises the question of whether such an approach would be feasible in oral ep-
ithelial cells derived from PMOLs, laying the basis for possible clinical studies of such
an approach in the chemoprevention of OSCC. In the present study, we aim to confirm
the de novo methylation of RARβ in oral epithelial dysplasia and understand its role in
cellular immortalisation and abrogation of cellular senescence. We test the hypothesis that
administration of 5-AZA-CdR alone and/or in combination with All trans-retinoic acid
(ATRA) leads to re-expression of RARβ, reversal of immortalisation, and reinduction of the
senescence programme in a panel of immortalised primary cultures.
2. Materials and Methods
2.1. Cell Lines and Culture Conditions
The experimental work described used a unique cohort of cell cultures derived from
a variety of potentially malignant oral lesions (PMOL), all part of the Beatson Institute
for Cancer Research cell culture collection. These have varied proliferative lifespans,
with some undergoing replicative senescence (D6 and D30), whilst others are immor-
tal (D19, D20, D34 and D38; Table 1). The p16−/TERT+ immortalised NOK culture
FNB6TERT was used as a control. The molecular features that define these cultures have
been previously described [16,27]. The cultures were maintained on an irradiated Swiss
3T3 feeder layer in Green’s medium at 37 ◦C with 95% humidity and 5% CO2. The medium
consisted of a 1:3 (v/v) mixture of Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 4500 mg/L glucose GlutaMAX™ I and sodium pyruvate (Gibco, Paisley,
UK) and Ham’s F12 medium supplemented with L-glutamine and sodium bicarbonate
(Biosera, East Sussex, UK) with heat-inactivated fetal calf serum (Biosera, East Sussex,
UK). This was supplemented with adenine (0.025 µg/mL) insulin (5 µg/mL), 3, 3, 5-Tri-
iodothyronine/Apo-Transferrin (1.36 ng/mL T3 and 5µg/mL apo-transferrin), hydrocor-
tisone (4 µg/mL), epidermal growth factor (5 ng/mL), amphotericin B (0.625 µg/mL),
cholera toxin (8.47 ng/mL), penicillin (100 IU/mL), and streptomycin (100 µg/mL). The
irradiated 3T3 feeder layer was removed by treatment with 0.05% trypsin/0.02% EDTA
(w/v) (Sigma Aldrich, Dorset, UK) before keratinocyte trypsinisation.
Table 1. Details of the PMOL cell lines used in the study with original diagnosis and expression of RARβ in the corresponding
parent tissues.
Cell Type Site Clinical Type Dysplasia Grade Phenotype RARβ Expression (%)
D6 Posterior tongue Leukoplakia Moderate Mortal (25PD) 59.2
D30 Floor of the mouth Leukoplakia Mild Mortal (30PD) 60.0
D19 Lateral tongue Erythroplakia CIS Immortal 4.4




Leukoplakia Moderate Immortal 25.1
D38 Lateral tongue Leukoplakia Mild Immortal 13.7
2.2. ATRA and 5-Aza-CdR Treatment of Cells
All-trans-retinoic acid (Sigma-Aldrich, Dorset, UK), dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 10−2 M, and stored in dark at −70 ◦C, was diluted in growth
medium to a final concentration of 10−6 M immediately before each experiment. Control
cultures received the same amount of DMSO as treated cultures. 5-aza-2′-deoxycytidine
(5-Aza-CdR) (Sigma, St. Louis, MO, USA) was dissolved in DMSO at a concentration of
2 × 10−3 M, stored in small aliquots the dark at −70 ◦C. Cell lines were treated with 0.5 µM
of 5-Aza-CdR with media refreshed every 24 h for 5 consecutive days before genomic DNA
and total RNA were extracted and tested for methylation status as well as restoration of
RARβ expression. RARβ2 induction was analysed in the cells treated using 1, 5, or 10 µM
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of ATRA for 3 days. Untreated cells were used as an experimental control, and cells treated
with a working concentration of DMSO were used as solvent control.
2.3. cDNA Synthesis and RT-qPCR
Total RNA from the cultured cell lines was isolated using RNeasy Mini Kit (Qiagen,
Manchester, UK) and treated with DNase I (Qiagen, Valencia, CA, USA). The quantity
and quality of DNA and RNA were analysed by 1000 NanoDrop Spectrophotometer V3.7
(Thermo Scientific, Hemel Hempstead, UK). An input amount of 2 µg was used for Reverse
transcription PCR, and cDNA synthesis was performed using a High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster, CA, USA) following manufacturer’s
instructions in the DNA Engine Dyad thermal cycler (Bio-Rad, Hercules, CA, USA).
Quantitative real-time PCR (qPCR) was performed using ABI Prism 7900 Fast Se-
quence Detection Instrument (Applied Biosystems, Foster, CA, USA) for the relative
gene expression of RARβ2 (Hs00977141_mH), CDKN2A, (Hs99999189_m1), CDKN1A
(Hs00355782_m1), IVL (Hs00846307_s1), ITGB1 (Hs05351551_g1), and CRBP1 (Hs01011512_g1),
with β-2-microglobulin (B2M) (Assay ID: Hs99999907_m1) as a housekeeping gene using
Taqman Assays procured from Thermo Fisher Scientific. All experiments were performed
in triplicate, analysis was carried out using 2ˆ−∆Ct method [28] to calculate the mRNA
expression relative to the B2M, and data was represented as mean with standard error.
2.4. Western Blotting
Following trypsinisation, cells (D6, D30, D34, D38, D19, D20, FNB6) were washed
in 1× PBS (pH 7.0) and lysed in RIPA buffer (Sigma Aldrich, Poole, UK) containing
protease and phosphatase inhibitors (Roche, West Sussex, UK). Protein preparation was
carried out by centrifugation of cells at 12,000 rpm, 4 ◦C for 20 min, following which
the supernatant was aspirated. The total protein concentration was determined using
Pierce BCA Protein Assay Kit as per the manufacturer’s protocol (Thermo Scientific, Hemel
Hempstead, UK). A total of 20 µg of total protein was loaded onto 4–12% polyacrylamide
precast gels (NuPAGE™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, Novex, Thermo
Scientific, Hemel Hempstead, UK). After transferring the gel onto nitrocellulose membrane
using an iBlot Dry Blotting System (Life Technologies, Carlsbad, CA, USA) for 7 min, the
membranes were washed with Tris buffer and blocked with 5% dried milk in Tris-buffered
saline (TBS) containing 0.05% Tween-20, for 1 h and incubated overnight at 4 ◦C with the
following primary monoclonal antibodies: (Anti-RARβ antibody (EPR2017; (ab124701))
at 1/1000 dilution; Anti-p21 antibody (EPR18021; (ab188224)) at 1/1000 dilution; Anti-
CDKN2A/p16INK4a antibody (DCS50.1; (ab16123)) at 1/5000 dilution and incubated for
1 h with primary anti-β-actin antibody (1:5000), Sigma Aldrich, Poole, UK). Membranes
were then incubated in horseradish peroxidase (HRPO) conjugated with anti-rabbit IgG
(1:3000, ab6721, Abcam (Cambridge, UK)) for 1 h and developed with SuperSignal West
Pico chemiluminescent substrate (Thermo Scientific, Hemel Hempstead, UK). HeLA and
irradiated 3T3 cells’ lysate were used as experimental controls.
2.5. Growth Inhibition Assay and Flow Cytometry
Cells were seeded at a density of 1 × 105 cells/well in a 6-well plate as required. Post
24 h, the cells were treated with different concentrations of ATRA, 0.5 µM 5-Aza-CdR and a
combination of 0.5 µM 5-Aza-CdR and 1 µM ATRA for 3 days in Green’s medium contain-
ing 10% FCS. The cells after the treatment were labelled with EdU (5-ethynyl-2′-deoxyuridine)
at a concentration of 10 µM for 1–2 h (Click-iT® EdU Alexa Fluor™ 488 Assay Kits for Flow
Cytometry, Life technologies; excitation 488 nm/emission 530 nm). EdU is a nucleoside
analogue to thymidine and is incorporated into DNA during active DNA synthesis. Follow-
ing EdU labelling, the cells were washed once with 3 mL of 1% BSA in PBS, pelleted, and
the supernatant removed. The cell pellet was dislodged, and 100 µL of Click-iT® fixative
was added and mixed well. Cells were incubated for 15 min in the dark, then washed
once with 3 mL of 1% BSA in PBS, pelleted, and the supernatant removed. Cells were
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resuspended in 100 µL of 1× Click-iT® saponin-based permeabilisation and wash reagent
and mixed well and incubated. Appropriate amounts of Click-iT® Plus reaction cocktail
was used within 15 min of preparation, and 0.5 mL of Click-iT® Plus reaction cocktail
was added for each tube, mixed well, and incubated for 30 min and protected from light.
Following this, the cells were washed once with 3 mL of 1× Click-iT® saponin-based per-
meabilisation and wash reagent and resuspended in 500 µL of 1× Click-iT® saponin-based
permeabilisation and wash reagent. A total of 50 µL of RNase (100 µg/mL solution) was
added and incubated for 15 min at 37 ◦C. Finally, the nucleic acid dye, TO-PRO-3 (Thermo
Fisher Scientific, excitation 643 nm/emission 661 nm), was added at a concentration of
0.1 µM and incubated for 15 min in the dark. Samples were analysed by flow cytometry
using an LSRII flow cytometer (Becton Dickinson, Oxford, UK) and FACSDiva™ versio
7 acquisition software (Becton Dickinson, Oxford, UK). Cells were gated based on forward
(FSC) and side (SSC) light scatter, and 10,000 events per sample were recorded. Data
were analysed using FlowJo analysis software v7.6.5 (Tree star Inc, Ashland, OR, USA).
Apoptotic cells in the sub-G0 region were excluded, and standard flow cytometry methods
were used for determining the percentage of G1/S/G2-phase cells in the population, as
previously described [29].
2.6. Promoter Methylation Analysis
Promoter methylation analysis was performed by MethylScreen technology [30], using
EpiTect Methyl II PCR Assay kit, Qiagen. Briefly, genomic DNA was extracted and purified
from the treated and untreated PMOL cell lines using QIAmp DNA mini kit and aliquoted
in equal amounts of DNA (250 ng) into four tubes labelled mock (M0), methylation-sensitive
(Ms), methylation-dependent (Md), and methylation-sensitive-dependent (Msd) restriction
enzymes. All four cocktail reaction tubes were incubated at 37 ◦C for 6 h and then at
65 ◦C for 20 min using DNA Engine Dyad thermal cycler (Bio-Rad, Hercules, CA, USA).
Quantitative PCR for determination of methylation status was performed in ABI Prism
7900 Fast Sequence Detection Instrument (Applied Biosystems, Foster, CA, USA) using
5 µL of remaining input genomic DNA post the restriction digestion with qPCR master mix
(RT2 qPCR SYBR Green/ROX Master Mix, Qiagen, Manchester, UK: Cat number 330520),
and were dispensed into a PCR array plate containing pre-aliquoted primer mixes (EpiTect
Methyl II qPCR Primer Assay) according to manufacturer instructions. Thermal cycling
conditions used were: 95 ◦C for 10 min (1 cycle), then 99 ◦C for 30 s and 72 ◦C for 1 min
(3 cycles), and finally, 97 ◦C for 15 s and 72 ◦C for 1 min (40 cycles). The raw Ct values
obtained post the run were pasted into EpiTect Methyl II PCR Array Microsoft Excel-based
data analysis template (supplied), which automatically calculates the relative amount of
methylated and unmethylated DNA fractions.
2.7. Methylation-Specific PCR (MSP) and Bisulfite PCR for Restriction Analysis
The promoter methylation status of RARβ was determined by MSP. Briefly, 2 µg of
genomic DNA was treated with sodium bisulfite for 16 h. Following this, DNA was desul-
fonated and purified using the Wizard DNA Clean-up system (Promega, Madison, WI,
USA). An input quantity of 2 µL of converted DNA was used as a template for performing
MSP with two sets of primers to differentiate between methylated and unmethylated re-
gions as described [31]. The primer sequences specific for methylated sodium bisulfite DNA
(FP: 5′-TCGAGAACGCGAGCGATTCG-3′ (sense) and RP: 5′-GACCAATCCAACCGAAACGA-
3′ (anti-sense); 146 bp, TH −58
◦C) and those for unmethylated sodium bisulfite DNA (FP:
5′-TTGAGAATGTGAGTGATTTGA-3′ (sense) and RP: 5′-AACCAATCCAACCAAAACAA-
3′; 146 bp, TH −50
◦C) were used [32].
Furthermore, methylation of the RARβ-promoter region was determined using com-
bined bisulfite PCR followed by restriction analysis as described earlier (COBRA) [33]. The
primer sequences used for amplifying the modified DNA were forward:
5′-AAGTAGTAGGAAGTGAGTTGTTTAGA-3′ and reverse: 5′-CCAAATTCTCCTTCCAAATAA-
3′ yields an amplicon of 207 bp product as published [17]. The amplified products were
Cancers 2021, 13, 4064 6 of 20
then digested with TaiI for RARβ2 (MBI Fermentas, Hanover, Germany) and subjected
to electrophoresis on 3% agarose gel and visualised using ethidium bromide. Human
methylated lymphocyte DNA generated in vitro by CpG methyltransferase (SssI; New Eng-
land Biolabs, Inc., Beverly, MA, USA) was used as a positive control and the non-template
(negative) control was included as in every PCR run.
2.8. DNA Cloning and Sequencing
Primers employed to generate the target region of interest for cloning were the same
used for COBRA to clone DNA fragments into a Pcr2.1 TOPO vector (Invitrogen Cor-
poration, Carlsbad, CA, USA) according to manufacturer’s instructions. The generated
vector construct was then transformed into chemically competent E. coli, and positive
colonies were selected based on blue–white screening for propagation. Plasmid DNA was
extracted and purified using Qiagen Plasmid Mini Kit (Qiagen, Valencia, CA, USA) and
sequenced using ABI PRISM 377 DNA sequencer (Applied Biosystems, Foster, CA, USA)
at the DNA-sequencing core facility at the University of Sheffield, UK.
2.9. Immunofluorescence
Cells were plated in eight-well glass chamber slides (Thermo Scientific™ Nunc™ Lab-
Tek™ Chamber Slide System) prior to processing. The 1 × 104 cells (D19, D20, D34, D38
and FNB6) were seeded onto coverslips and cultured until they reached 95% confluence.
Cells were fixed in 4% paraformaldehyde for 15 min and permeabilised using Triton-X-100
(Sigma, Poole, UK) for 15 min. Blocking of non-specific binding was carried out using
unlabelled serum from the same species as the second antibody for 1 h at room temperature.
Samples were incubated with the primary antibody Anti-HIRA/HIR antibody (EPR7416)
(ab129169) at 1:200 dilution at 4 ◦C overnight. Goat anti-rabbit IgG (Alexa Fluor® 488,
ab150077) was used as the secondary antibody at 1:1000 (2 µg/mL) dilution for 1 h at
room temperature (RT). Cells were counterstained with DAPI (Invitrogen) for 10 min
at RT in the dark. 1× PBS with 0.05% Tween-20 was used throughout the protocol for
adequate washing. Coverslips were mounted on microscopic slides with antifade solution
(VectaShield, Vector Laboratories, Burlingame, CA, USA). Cells incubated with IgG and
secondary antibodies served as a background control. Stained cells were examined using
a Leica DMRB fluorescence microscope and ×40/0.7 objective lens (Leica Microsystems,
Wetzlar, Germany); for these experiments, image processing was performed by LAS AF
software (Leica Microsystems). Three or more foci per nucleus were considered to be
positive for HIRA.
2.10. Senescence β-Galactosidase Staining
Senescent keratinocytes were identified using Senescence β-Galactosidase Staining
Kit (Cell Signalling Technology, Inc., Beverly, MA, USA). β-Galactosidase Staining Solution
at final pH of 6.0 stain positively for senescent cell, as described by [34]. Briefly, cells
were grown on a 35 mm Petri dish, washed once with PBS, fixed with PBS containing
2% formaldehyde and 0.2% glutaraldehyde, then washed in PBS supplemented with 1 mM
MgCl2. Cells were stained in senescence-associated β-galactosidase staining solution
(150 mM NaCl, 2 mM MgCl2, 5 mM potassium ferricyanide, 40 mM citric acid, and 12 mM
sodium biphosphate, at pH 6.0. containing 1 mg/mL of 5-Bromo-4-chloro-3-indolyl β-D-
galactoside overnight at 37 ◦C in a dry incubator without CO2. The plates were sealed with
parafilm to prevent evaporation. For long-term storage of the plates, staining solution was
removed, and the cells were overlayed with 70% glycerol and stored at 4 ◦C. To ensure
a representative count, each culture was divided into quarters, and at least two fields
were photographed with an Olympus IMT-2 phase-contrast microscope. A minimum of
500 cells was counted on each occasion. The percentage of senescent cells present was
defined as the percentage of senescence-associated β-galactosidase positive cells out of
the total number of cells present. Average percentages and SD were calculated from three
independent experiments.
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2.11. Tissue-Engineered Oral Mucosa
De-epidermised acellular dermis was incubated in fresh DMEM for 48 h at 37 ◦C
to confirm sterility. Processed DED was cut into 2 cm × 2 cm squares and placed into
6-well plates submerged in Green’s media. Chamfered surgical stainless-steel rings with
an internal diameter of 8 mm were pushed onto the DED to provide a liquid-tight seal. For
the tissue-engineered dysplastic oral mucosa models (TEDOM), 2.5 × 105 D6, D30, D34,
D38, D19 and D20 cells and 5 × 105 normal oral fibroblasts (NOFs) was used. Medium
within the ring was replaced after 24 and 48 h. After 72 h, the ring was removed, and the
composites were placed onto stainless steel grids with medium added to the underside
of the composite model to allow culture at the air-to-liquid interface. For all models,
the medium was changed 2–3 times/week, and the composites were fixed at day 14 for
TEDOM in 10% buffered formalin for 48 h [35].
2.12. Patient Tissue Samples and Immunohistochemistry
Two cohorts of patient samples were analysed by immunohistochemistry: one whose
samples directly matched the cell cultures used in the main part of the project (n = 6)
and a separate, unrelated cohort of oral premalignant lesions (n = 10). Oral precancerous
tissues from surgically excised oral dysplasia lesions representing different grades of
dysplasia and adjacent normal mucosal tissue from the archive of the Department of Oral
and Maxillofacial Pathology, University of Sheffield. RARβ expression was assessed by
immunohistochemistry in a cohort of dysplastic lesions of various grades with a particular
emphasis on tissue heterogeneity. All the original histological diagnoses were reviewed by
two independent examiners (RR and KDH). Then, 4 µm sections were cut from FFPE blocks
and mounted on APES coated slides. Deparaffinization and hydration of the tissue sections
were carried out through two changes of xylene and graded alcohols. Heat-induced
antigenic epitope retrieval was carried out in Sodium citrate buffer (10 mM Sodium Citrate,
0.05% Tween-20, pH-6.0). After washing sections twice in TBS +0.025% Triton-X-100 with
gentle agitation, sections were blocked in 10% normal serum with 1% BSA in TBS for 2 h
at room temperature. After draining slides, an anti-RARβ antibody (EPR2017) (ab124701)
was added at 1:100 dilution in TBS with 1% BSA and incubated overnight at 4 ◦C. The
following day, sections were rinsed twice in TBS with 0.025% Triton-X-100 with gentle
agitation. Sections were then incubated in a biotinylated secondary antibody (Vectastain
Elite ABC Kit) for 30 min. Following a 2 × 5 min wash in TBS, sections were incubated with
VECTASTAIN Elite ABC reagent for 30 min, washed, and visualisation was developed
with 3,3′-Diaminobenzidine (DAB). Eventually, sections were counterstained, dehydrated,
cleared, and mounted.
Each spot image was submitted to colour deconvolution to separate the blue colour
from haematoxylin and the brown colour from DAB using the plugin in ImageJ software
(National Institute of Health, Bethesda, MD, USA). The positive labelling (brown colour)
was selected using the threshold tool of ImageJ (from 0 to 127 brown tones). First, the
image was processed by colour deconvolution using the two vectors, hematoxylin and DAB.
Assessment of intensity was not carried out as the immunostains are not stoichiometric.
Then, the processed image was adjusted for optimal threshold. The upper and the lower
limit for both the DAB alone and hematoxylin was adjusted and the particles in both were
separately analysed. The final score was calculated as ((positive labelling area/tumour
area) × 100)). A qualitative interpretation of immunohistochemical signal was performed,
blinded to diagnosis and clinical data.
2.13. Statistical Analysis
The data analysed was represented as mean with standard error derived from at
least three independent experiments. Comparisons among the groups were performed
using one-way ANOVA followed by post hoc Tukey’s test or Dunnett’s test. Compar-
ison between the two groups was performed using paired or unpaired t-tests. All the
statistical analysis mentioned was performed using GraphPad prism statistical software
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v8.0 (GraphPad Software Inc., San Diego, CA, USA). A p-value of <0.05 was considered
statistically significant.
3. Results
3.1. RARβ2 Expression Is Lost in iPMOL Cultures and Reduced in Their Matched Tissues, but
Expression Varies in All PMOL Tissues
RARβ2 is expressed by mortal PMOL cells (D6 and D30), whereas expression has
been lost in immortal OPML (iPMOL) cell cultures (D19, D20, D34 and D38) and the
immortalised NOK culture FNB6 (Figure 1A), as assessed by qPCR. Total RARβ protein
expression was reduced in iPMOL cells (Figure 1B). In keeping with earlier reported
patterns of expression in these cells, there is lower p16 and p21 expression in the immortal
cells [14,16,27]. Markers of differentiation (IVL and ITB1) and expression of cRBP1 are also
reduced in iPMOL cells (Figure 1A,B).
The extent of RARβ expression in the biopsy samples matched to the cell cultures
shows that RARβ expression was lower in the tissues that gave rise to immortal cell cultures
(Figure 1C; Table 1). This indicates that the loss of RARβ expression is not merely an in vitro
phenomenon. Nevertheless, all tissues did express RARβ to some extent, indicative of
a mixed cell population in these PMOL tissues, as we have previously suggested [36].
Expression of RARβ in an extended clinical cohort (n = 10) confirmed this heterogeneity
in the expression of RARβ2 (Figure 1D). The proportion of cells expressing RARβ2 was
variable and was not directly related to the grade of epithelial dysplasia (Table 2). The
expression of cRBP1 in this biopsy cohort was very variable. RARβ staining in the 3D tissue-
engineered oral mucosa (TEM) models developed from iPMOLs showed a heterogeneous
staining pattern, but which was higher overall than in the parent tissue biopsies (Figure 1E).
Table 2. Details of the extended OED patient cohort.





P1 F 75 Mandibular Gingiva Mild 51.2
P2 M 71 Ventral Tongue Moderate 57.0
P3 M 36 Floor of mouth Severe 44.9
P4 M 60 Soft Palate Mild 53.2
P5 F 57 Floor of mouth Moderate 32.8
P6 M 73 Lateral Tongue Mild NED
P7 M 57 Ventral Tongue Mild 60.9
P8 M 62 Lateral Tongue Moderate 46.1
P9 M 42 Lateral Tongue Severe 41.0
P10 M 41 Ventral Tongue Moderate 43.1
NED: no expression detected.
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Figure 1. Baseline expression of RARβ2 mRNA and total RARβ protein levels in PMOL cell lines and tissues. (A) Assessment of baseline RARβ2 mRNA expression by qPCR demonstrated
significantly higher expression in mPMOL cells (D6 and D30) compared to the iPMOL cells and FNB6TERT cells (p < 0.03). The mRNA expression of cell cycle regulators, CDKN1A and
CDKN2A, was also higher in the mPMOL cells when compared to iPMOL cells (p < 0.002) and higher expression of cRBP1 and differentiation markers ITGB1 and IVL was also observed
(p < 0.05, Kruskal–Wallis test). (B) Western blotting of total RARβ, CDKN1A, and CDKN2A with β-actin as a loading control. HeLa cells and i3T3 cells were added as experimental
controls. These show a similar pattern of expression to that seen in the qPCR, albeit the Western blot shows total RARβ, rather than RARβ2. (C) Immunohistochemical expression of total
RARβ in the FFPE biopsy tissues corresponding D6, D30, D19, D20, D34, and D38 showed lower RARβ expression in tissues from which iPMOLs were derived compared to those from
which mPMOLs were generated. (D) Immunohistochemical expression of RARβ in the extended clinical cohort (n = 10) demonstrated variable proportions of total RARβ expression,
which was not related to the grade of epithelial dysplasia. (E) Immunohistochemical expression of RARβ in 3D TEM models constructed using iPMOL cells showed variable staining for
RARβ, but in every case, higher than in the matched biopsy material (Figure 2C).
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Figure 2. Promoter methylation analysis of the RARβ gene. (A) The proportion of RARβ-promoter methylation in D19, D20, D34, and D38 iPMOL cell lines, without (untreated) and
treated with 5-AZA-CdR, as detected using the EpiTect Methyl II PCR Assay kit. The % of promoter methylation in D19, D20 and D34 reduced on treatment with 5-AZA-CdR (* p < 0.0001,
** p < 0.0017, *** p < 0.0001 **** p< 0.00005), whereas in D38, the promoter was completely unmethylated prior to treatment. (B) Using methylation-specific PCR on DNA from 5-AZA-CdR
untreated and treated cells, the RARβ-promoter region (146 bp, consisting of 14 CG sites), was amplified using primers specific for methylation (M) and unmethylation (U), and the
products run on a 3% agarose gel. In D19, D20, and D34 cell lines, there was decrease in the intensity of the methylated band’s intensity after treatment with 5-AZA-CdR. (C) Using
bisulfite-specific primers in both treated (+) and untreated (−) cell lines, a 207 bp promoter region was amplified by PCR. Bands in the gel represent this product which was subsequently
treated with TaiI restriction enzyme. (D) Treatment of the 207 bp product with TaiI restriction enzyme demonstrates differing sizes of methylated (larger fragment; upper band) and
unmethylated (smaller fragment: lower band) fragments. The proportion of methylated and unmethylated fragments are altered in D19 and D34, and there is a reduction in the methylated
fragment in D20. The unmethylated RARβ-promoter region in D38 remained unchanged before and after treatment. This pattern of alteration is in keeping with the EpiTect Methyl II PCR
and Methylation-specific PCR data. (E) Sequencing of the bisulfite-treated DNA 207 bp product allowed calculation of the percentage of methylation at specific sites in the promoter
(11 sites). The figure shows representative electropherograms of bisulfite sequencing reads from all iPMOL cells and FNB6TERT. From these, the percentage of CG methylation was
calculated by comparing the peak height of cytosine with the sum of the heights of cytosine and thymine signals as represented. Abbreviation. UM = unmethylated fraction of DNA;
M = methylated fraction of DNA; (+) treated; (−) untreated.
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3.2. The RARβ-Promoter Was Hypermethylated in 3/4 Immortal Oral Dysplastic Cell Lines
Analysis of DNA methylation of the RARβ-promoter region was performed using
Epitect Methyl II qPCR assay specific for RARβ-promoter CpG island (GenBank: X56849.1).
The RARβ promoter was hypermethylated in D19 and D34 cells, with the methylated
fraction of DNA noted to be 71.12% and 51.91%, respectively. A significant reduction
in methylation was noted after treatment with 5-AZA-CdR (p < 0.001). The methylation
level in the D20 cells was 11.76%, which was lower than seen in D19 and D34. However,
significant de-methylation was noted upon treatment with 5-AZA-CdR (p < 0.0017). In D38,
the RARβ promoter was unmethylated and showed no change with treatment (Figure 2A).
To eliminate the potential false positives and to confirm the extent of methylation,
methylation-specific PCR was carried out. Methylation-specific PCR of bisulfite-treated
DNA from four IMDs showed a 146 bp transcript using primers specific for methylated
(M) and unmethylated (U) DNA in the untreated (−) and treated (+) cells. A reduction
in the band intensity in D19 and D34 and a modest reduction in D20 were noticed when
treated with 2 µM 5-AZA-CdR. The D38 cells remained unchanged in both the methylated
(M) and unmethylated (U) lanes before and after treatment (Figure 2B).
Further validation of DNA methylation and de-methylation by the action of 5-AZA-
CdR was confirmed by bisulfite sequencing. This was followed by COBRA, where a
207 bp of bisulfite modified DNA of the promoter was amplified, and the PCR product was
digested using the TaiI restriction enzyme, which specifically cuts at ACGTˆ sites generating
upper unmethylated and a lower methylated DNA fragment, whereas unmethylated DNA
remained uncut (Figure 2C,D). Analysis of the 11 CG sites in all the iPMOL cells was
determined by sequencing followed by comparing the peak height of cytosine with the
sum of the height of cytosine and thymidine signals (Figure 2E).
3.3. Treatment with 5-Aza-CdR and ATRA Variably Alters Expression of RARβ, p16, and p21 in
iPMOL Cells
The extent of expression of RARβ in D19, D20, D34 and D38 was assessed after treat-
ment of the cells with various concentrations of ATRA and 5-AZA-CdR separately and in
combination. In D19 and D34, RARβ expression was highest (p < 0.0001) when treated with
a combination of 0.5 µM 5-AZA-CdR and 1 µM ATRA. A concomitant increase in CDKN1A
(p < 0.0001) and CDKN2A (p < 0.002) expression was noted when the cells were treated
with ATRA and 5-AZA-CdR alone and/or in combinations (Figure 3A,B). D20 showed a
re-expression of RARβ (p < 0.0001) when treated with 5-AZA-CdR and ATRA combination,
and CDKN1A re-expression was significant on treatment with 10 µM ATRA (p = 0.0001),
but changes in CDKN2A expression were not statistically significant (Figure 3A,B). In
D38, RARβ was re-expressed on ATRA treatment (p < 0.03). CDKN1A was expressed on
treatment with ATRA in combination with 5-AZA-CdR (p < 0.0001), whereas there was
no significant difference in CDKN2A expression (Figure 3A,B). Although the combination
of 5-AZA-CdR and ATRA produced the highest levels of RARβ in iPMOL cells, ATRA
or 5-AZA-CdR alone when used in varying concentrations induced RARβ re-expression
(p < 0.05). These results imply that the response is cell-line-specific and dose-dependent.
In 3D TEM models, RARβ staining of the models showed a significant increase
in expression after treatment with ATRA (Figure 3C and Table 3). Under 5-AZA-CdR
treatment (alone or in combination with ATRA), the 3D TEM models were insufficiently
robust for further assessment (included for completeness in Figure 3C).
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Figure 3. Expression of RARβ and cell cycle markers in iPMOL cells when treated with varying concentrations of ATRA and 5-AZA-CdR used either alone or in combination. (A) Expression
RARβ2, CDKN1A, and CDKN2A was assessed by qPCR in D19, D20, D34, and D38 cells after treatment with varying doses of ATRA, 5-AZA-CdR alone, or a combination of 5-AZA-CdR
and ATRA. Increased expression of RARβ was noted in D19, D20, and D34 (p < 0.0001) when treated with a combination of 5-AZA-CdR and ATRA or 5-AZA-CdR alone. A concomitant
increase in expression of CDKN1A and CDKN2A was observed in D19 and D38 (p < 0.002). D38 showed an increase in the CDKN1A expression proportionate to the re-expression of
RARβ on treatment with ATRA and a combination of 5-AZA-CdR and ATRA (p < 0.0001). Repeated-measures one-way ANOVA with post hoc Tukey’s test was performed to determine
the statistical significance (p < 0.05). M = methylated; UM = unmethylated. (B) Western blotting for RARβ, CDKN1A, and CDKN2A upon treatment with the varying concentrations of
ATRA and 5-AZA-CdR or in combination confirmed their re-expression in the iPMOL cells. M = methylated; U = unmethylated. (C) Expression of RARβ was assessed in 3D TEMs
constructed using each of the iPMOL cells by immunohistochemistry. The matched untreated TEMs are shown in Figure 1E. Total RARβ staining of the untreated and treated cells with
ATRA showed a significant difference in 3D tissue-engineered oral mucosal models before and after treatment. The models were insufficiently robust to withstand the combination of
ATRA and 5-AZA-CdR.
Cancers 2021, 13, 4064 13 of 20
Table 3. RARβ expression in 3D-tissue-engineered oral mucosa models before and after treatment
with 1 µM ATRA.





We also identified changes in the expression of cRBP1 in these cultures (Figure 1A
and Figure S1). Treatment with 5-Aza-CdR and 5-Aza-CdR + ATRA resulted in increased
expression in D34 and D20, with little effect in D19 and D38 (Figure S1). The mechanism of
this is unclear as the cRBP1 promoter did not show CpG island methylation in any case.
3.4. Treatment with 5-Aza-CdR and ATRA Increases the Proportion of Senescent iPMOL Cells
The HIRA foci assay showed an increased accumulation of senescence-associated
heterochromatin foci (SAHF) in iPMOL cells when treated with the combination of 5-AZA-
CdR with ATRA (p < 0.0007: Figure 4A). D34 and D38 cells also showed a significant
increase in HIRA foci when treated with varying concentrations of ATRA (p < 0.0001) or
5-AZA-CdR (p < 0.002) (Figure 4A).
The mean percentage values of senescence-associated β-galactosidase (Saβ-gal) activ-
ity increased upon treatment with ATRA and 5-AZA-CdR in D20, D34, and D38 (p < 0.0001)
cells, and less so in D19, when compared to untreated cells (Figure 4B). However, D38
cells showed relatively uniform SA-β-gal positivity across the concentrations tested with
or without combination, with only a small but significant increase (p < 0.0002). As with
the HIRA foci assay, D34 and D38 cells showed a significant increase in SA-β-gal activity
when treated with the various concentrations of ATRA or 5-AZA-CdR when compared to
untreated cells (p < 0.0002: Figure 4B).
3.5. ATRA and 5-AZA-CdR-Treated IMDs Show G2/M Arrest and Increased Sub-G0 Phase
Treatment of the iPMOL cells with 5-AZA-CdR and 5-AZA-CdR + ATRA resulted
in accumulation of cells in the G2 phase of the cell cycle in D19, D20, and D34, with little
effect seen in D38 (Figure 5A–E) when compared to vehicle control (DMSO). The effect
appeared to be primarily mediated by 5-AZA-CdR, as ATRA alone had little effect nor
further increased the G2 accumulation seen when used in combination with 5-AZA-CdR.
Treatment with ATRA between 5–10 µM increased the proportion of cells in G1 for D19
only (Figure 5D), with a corresponding decrease of newly synthesised DNA. Apoptosis
was assessed by quantifying sub-G0 content, which typically represents fragmented DNA.
A small increase in sub-G0 events was seen with 5-AZA-CdR treatment of D19 cells (2.92%
vs. 0.73% vehicle control: Figure 5C); this is unlikely to account for the significant reduction
in S-phase DNA.
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Figure 4. Senescence in ATRA and/or 5-AZA-CdR treated iPMOLs was assessed by assessment of SAH foci and SA-β-gal activity assay. (A) Assessment of senescence-associated
heterochromatic foci (SAHF) was undertaken using immunofluorescent assessment of HIRA. The mean frequency of HIRA foci showed a higher accumulation in iPMOL cells (D19, D20,
D34, and D38) when treated with the combination of 5-AZA-CdR with ATRA or alone compared to the control (p < 0.0007). (B) Mean percentage values of SA-β-gal positive cells were
significantly higher in D20 and D34 cell lines (p < 0.0001) than in D19 and D38 when compared to the untreated controls. D34 and D38 cells showed significant increase in the HIRA foci
and SA-β-gal activity even when treated alone with the various concentrations of ATRA and/or 5-AZA-CdR. Statistical significance was determined using one-way ANOVA with post hoc
Dunnett’s test (p < 0.05).
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Figure 5. Cell cycle analysis and the sub-GO content by flow cytometry. (A) A representative image of cell cycle analysis showing G1-S-G2M peaks assessed by flow cytometry with
EdU in ATRA and 5-AZA-CdR treated D19 cells. (B) A representative flow cytometry dot plot of EdU-labelled D19 following treatment with ATRA, 5-AZA-CdR, and a combination of
5-AZA-CdR with ATRA showing a slowdown of cell turnover and G2-M arrest. (C) Representative histogram of treated D19 cell line highlighting sub-G0 content of fragmented DNA from
the apoptotic cells. (D) The bar charts represent a summary of the proportions of cells in cell cycle phases G1, S, and G2 in D19, D20, D34, and D38 under various treatment conditions.
(E) The bar chart represents the cell turnover with ATRA and a block in G2/M phase transition with 5-AZA-CdR and ATRA. An increase in G2-M phase cell accumulation was noted in the
D19, D20, and D34 cell lines (p < 0.05), whereas no significant difference was noted in the D38 cell line by one-way ANOVA with post hoc Tukey’s test.
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4. Discussion
The potential of the combination of effects of a methylating agent, such as 5-AZA-CdR
with retinoids, has been explored in a number of different malignant and pre-neoplastic
conditions [23–25]. The observation of loss of expression of some retinoid receptors by
promoter methylation, associated with loss of retinoid sensitivity and thus retinoid-related
modulation of differentiation and cell cycle arrest, indicates that this is potentially a
useful concept for chemoprevention. However, cell culture data in many cases have been
conducted on a very limited panel of cells, and, in some publications, only one. This leaves
several open questions as to the variability of response which may be associated with
the biological variability seen in the development of cancer and pre-neoplastic conditions.
Proof of principle has already been established in PMOL and OSCC [16,17], but an in-depth
assessment of the variability of response at the level of the effects on the cell cycle and
replicative potential has not been reported.
Whilst the loss of RARβ expression has been reported in OSCC tissues, this has not
been explored in PMOL tissues. Previous work, confirmed and extended in this report,
has demonstrated that RARβ2 expression is lost in most immortal oral precancer cells
(Figure 1A: [14]). This pattern of expression is reflected, to some extent, in the original
tissues, but tissue expression of RARβ varies. The tissues used for this assessment are those
from the original diagnostic biopsy, from which half of the sample was used to derive the
cell culture. The IHC staining pattern demonstrates that dysplastic oral mucosa consists
of a mixed cell population of RARβ expressing and RARβ negative cells. Whilst it has
not been possible to directly correlate this with other elements of the immortal pheno-
type in these tissues (p53 mutations, p16 loss, Telomerase activation), other studies have
reported heterogeneity in PMOL oral mucosa, for example, the appearance of “patches”
of p53 mutation, indictive of heterogeneous cell populations [37]. Given that some of the
PMOL tissues gave rise to cell cultures that can senesce, it is likely that these lesions contain
populations of cells with a mixed proliferative potential, and indeed, some cells may be
senescent or at least retain the potential to senesce. The retention of these cells within
PMOL mucosa may give the lesion a variable ability to respond to retinoids, as seen in the
numerous clinical studies reported over many years [6,8–10]. The expression of RARβ in
the TEM models is higher than in the original parent tissues (Figure 1E), which is expected
when using a single cell population for the generation of these models: however, there is
variability in expression, and an increase in expression is seen on ATRA treatment (Table 3).
This may indicate complex effects of differentiation in the 3D model which are not seen in
monolayer culture and which will require further investigation.
Previous studies of retinoid receptor expression in PMOL tissues are very limited and
hampered by a lack of sufficiently specific antibodies: indeed, the antibodies used in this
study have been challenging to use. They are not specific for RARβ2 and will pick up other
RARβ isoforms, which may explain the discrepancies between the qPCR and WB data. The
overall expression of RARs and RXRs appears to be increased in PMOL and SCC, indicating
complex changes in the spectrum of retinoid receptors in OSCC development [38,39], but
protein expression of subtypes beyond this has not been reported. Studies using in situ
hybridisation for RAR and RXR mRNA demonstrate loss of RARβ expression in about 50%
of lesions with a further reduction in OSCC, keeping with our findings [40].
RARβ2 is re-expressed following administration of 5′AzaC to a variable extent:
markedly in 2/4 cell lines tested (D19 and D34), to a much lesser degree in one (D20), and
not at all in another (D38: Figure 2A). D38 is unusual in as much as it is immortal but has
retained wild type p53 [16]. It also has retained the ability to increase RARβ expression on
treatment with ATRA (Figure 3). In most of these iPMOL cell cultures, the lack of RARβ
expression is accompanied by methylation of CpG islands in the RARβ promoter (Figure 2).
The modulation of RARβ expression by this mean appears to be an initial, reversible effect
in oral cancer development, as tissues from later in the process show loss of expression
by non-reversible means, such as chromosome 3p deletion [41]. Mortal oral precancer
cells retain RARβ2 expression (D6 and D30: Figure 1A), and this is constitutive, rather
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than only upon RA exposure, which would normally be the case in normal oral epithelial
cells [14]. In D20, the dynamic range of the increase in RARβ2 expression is much less than
in D19 and D34. Furthermore, treatment with 5-AZA-CdR does not result in an increase in
unmethylated CpG islands on the RARβ promoter; thus, the effects seen may be unrelated
to any effect on this promoter.
Expression of the retinoid-binding protein cRBP1 is also increased in D20 and D34
on treatment with 5-AZA-CdR, with no additional effect of ATRA treatment (Figure S1).
No change in expression was noted in D38. Parallel changes in cRBP1 expression may be
required for retinoid function.
In cells that re-express RARβ2, treatment with ATRA and 5-AZA-CdR in combination
results in accumulation of cells in G2 (Figure 5) and increases in the senescence markers
SAB-Gal and HIRA (Figure 4). The cell cycle effects seen are maximal on treatment with
5-Aza-CdR alone, and the addition of ATRA results in little additional change. This
maintains the known effects of 5-AZA-CdR treatment on the cell cycle, which initiates a G2
arrest [42]. As retinoids induce cell cycle arrest in G1 [43], it appears that the effects of these
treatment schedules on the cell cycle are dominated by the overall effect of 5-AZA-CdR.
This somewhat calls into question the additional benefit of ATRA treatment. However,
in relation to senescence, the addition of ATRA confers an additional increase in the
proportion of cells exhibiting senescence markers in D19 and less so in D20. Additionally,
treatment with 5-AZA-CdR increases the proportion of cells with markers of senescence in
D34, as has been previously reported [16]. This is not further increased by the addition to
ATRA. There is very little effect on the cell cycle or on senescence markers in D38.
The effects seen on the expression of p16ink4a and p21 support the cell cycle effects
seen. In D19 and D34, in which the most marked effects on the cell cycle are seen, treatment
with 5-AZA-CdR results in expression of p16ink4a and p21, whilst no effects were seen in
D20. Conversely, D38, which has wild-type p53, shows strong induction of p21 on 5-AZA-
CdR and combined 5-AZA-CdR +ATRA treatment (Figure 5A), but no consistent effects
on ether the cell cycle or induction of senescence. Loss of p16ink4a expression, initially by
promoter methylation, has been demonstrated as an early event in OSCC development and
has been described in PMOLs [44,45]. Thus, some of the effects seen in the cell cycle and
senescence may be due to the re-expression of p16ink4a mediated by 5-AZA-CdR. However,
p16 mediated pro-senescence effects have long been associated with arrest in G1, which
has not been demonstrated in this study. More recent investigations have shown that the
senescence program can be initiated in G2 and that p21 is an important mediator of this
process [46]. Whilst it is possible that some of the effects on the expression of p21 indicate
that senescence is also being induced via p21 at this point in the cell cycle (in addition to
the direct 5-AZA-CdR-mediated accumulation of cells in G2), the lack of effects seen in
D38, which has retained WTp53, does not support this conclusion.
Overall, the results presented demonstrate the variability in response to these agents
in cell culture. Response to treatment (defined as an increase in senescence markers and/or
alteration in the cell cycle) is variably related to the ability to re-express RARβ2, cRBP1,
and p16ink4a in iPMOL cells, but the majority of the effect is seen upon treatment with
5-Aza-CdR alone, with only modest additional effects on treatment with ATRA, even
in circumstances where RARβ is re-expressed. Assessment of all these factors would
be needed in patient samples to predict the response to therapy with retinoid and de-
methylation agents. Furthermore, it is true that assessment of these effects in monolayer
cell culture is sub-optimal for assessment of effects (particularly in the assessment of effects
on differentiation and the potential effects of the stroma on retinoid metabolism) and use of
a more robust 3D TEM model may be required [47]. Our initial investigations of this have
found that 3D mucosal models produced using our standard procedures are insufficiently
robust to withstand 5-Aza-CdR treatment (Figure 3C).
However, the effects on the D34 effect suggests that a beneficial effect may be possible,
as has been previously suggested [16]. As most of the effects seen in this cell culture system
are mediated by 5-Aza-CdR, it is unclear how much extra benefit is gained by the addition
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of ATRA. Additionally, increased efficacy has been demonstrated in other 2D and 3D cell
culture systems by the use of newer synthetic retinoids [48], and investigation of the effects
of these may also demonstrate increased effects in oral cells.
5. Conclusions
In conclusion, RARβ is constitutively expressed in the mortal dysplastic cells, which
undergo replicative senescence. Loss of RARβ by promoter methylation, along with
the inactivation of p16 and activation of telomerase, is associated with immortalisation
in dysplastic keratinocytes. Treatment of immortal dysplastic cells with 5-AZA-CdR in
combination with ATRA leads to the re-expression of RARβ (and in some cases, p16),
with a resultant increase in senescence. The explanation for the repression of RARβ
expression in D19, D20, and D34 was promoter hypermethylation, emphasising epigenetic
mechanisms in oral cancer pathogenesis, and the importance of the combination of drugs
for chemoprevention. However, defining the extent to which ATRA per se contributes to
these effects is difficult, given the wider effects of 5-AZA-CdR in these cells.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13164064/s1, Figure S1: Expression of cRBP1 under AZA-C and ATRA treatment as
assessed by qPCR. The pattern of expression in D19 is very similar to that in D34.
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